Orexigen Therapeutics Announces Spanish Launch of Mysimba in Partnership with Laboratorios Farmace´uticos Rovi
January 25, 2017 at 06:10 pm IST
Share
Orexigen Therapeutics, Inc. announced that Laboratorios Farmace´uticos Rovi, S.A. (ROVI) has launched Mysimba in Spain. Mysimba is approved by the European Medicines Agency for the management of weight in adult patients (=18 years) with an initial Body Mass Index (BMI) of = 30 kg/m2 (obese), or = 27 kg/m2 to < 30 kg/m2 (overweight) in the presence of one or more weight-related co-morbidities (e.g., type 2 diabetes, dyslipidaemia, or controlled hypertension). ROVI will market Mysimba as part of their diversified pharmaceutical portfolio under the terms of distributorship agreement signed in August 2016.
Laboratorios Farmaceuticos Rovi, S.A. specializes in the research, development, manufacturing and marketing of biological medications and specialty drugs. Net sales break down by family of products as follows:
- pharmaceutical products manufactured under contract (49%);
- prescription pharmaceuticals (45%): intended for preventing and treating venous thrombo-embolic disease, post-menopausal osteoporosis, muscle pain, tooth and mouth infections, angina, osteoarthritis, etc.;
- diagnostic products (6%): contrast products used in medical imaging with magnetic resonance, ultrasound, or X-rays. The group also offers hospital products and non-prescription pharmaceuticals.
Net sales break down by source of revenue between sales of products (50.6%), sales of services (49.3%) and sales of licenses (0.1%).
Net sales are distributed geographically as follows: Spain (33%), European Union (17.3%), OECD countries (45.9%) and other (3.8%).
LABORATORIOS FARMACEUTICOS ROVI, S.A. 
